Outcomes and Predictors of Stroke After Transcatheter Aortic Valve Replacement in the Cerebral Protection Device Era

Shashank Shekhar1, Toshiaki Isogai1, Ankit Agrawal1

  • 1Department of Cardiovascular Medicine, Heart Vascular and Thoracic Institute, Cleveland Clinic Cleveland OH USA.

Insights

Cerebral protection devices (CPDs) during transcatheter aortic valve replacement did not lower overall stroke risk but reduced major strokes. CPD use was linked to better outcomes, including shorter hospital stays and lower readmissions.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Neurosurgery

Background:

  • Transcatheter aortic valve replacement (TAVR) is a growing procedure for aortic stenosis.
  • The effectiveness of cerebral protection devices (CPDs) in preventing stroke during TAVR remains debated.
  • Existing studies report inconclusive findings regarding CPDs' impact on neurological outcomes.

Purpose of the Study:

  • To investigate the association between cerebral protection device (CPD) use and stroke rates in TAVR patients.
  • To analyze national data on stroke incidence and other clinical outcomes in TAVR procedures with and without CPDs.
  • To evaluate the impact of CPDs on major stroke, mortality, length of stay, and readmission rates.

Main Methods:

  • Analysis of the Nationwide Readmissions Database (2017-2020).
  • Inclusion of patients who underwent transcatheter aortic valve replacement (TAVR).
  • Comparison of outcomes between patients with and without CPD use using multivariable logistic regression.

Main Results:

  • CPD use was not associated with lower overall stroke rates (1.6% vs. 1.9%).
  • CPD use was significantly associated with lower major stroke rates (1.2% vs. 1.5%; P=0.02).
  • CPD cohort showed shorter length of stay, higher routine discharge rates, lower mortality, and reduced 30- and 180-day readmissions.

Conclusions:

  • CPD use during TAVR is not independently linked to reduced overall stroke risk.
  • CPD use is associated with a lower risk of major stroke.
  • Further randomized trials are needed to clarify patient selection and confirm benefits, addressing potential confounders.
Abstract